Fate Therapeutics, Inc. - Product Pipeline Review - 2012

Summary

“Fate Therapeutics, Inc. - Product Pipeline Review - 2012” provides data on the Fate Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Fate Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Fate Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Fate Therapeutics, Inc. - Brief Fate Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Fate Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Fate Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Fate Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Fate Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Fate Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Fate Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Fate Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Fate Therapeutics, Inc. and identify potential opportunities in those areas.

Table of Contents 2
List of Tables 4
List of Figures 4
Fate Therapeutics, Inc. Snapshot 5
Fate Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Fate Therapeutics, Inc. – Research and Development Overview 6
Key Therapeutic Areas 6
Fate Therapeutics, Inc. – Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products – Monotherapy 9
Fate Therapeutics, Inc. – Pipeline Products Glance 10
Fate Therapeutics, Inc. Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Fate Therapeutics, Inc. – Early Stage Pipeline Products 11
Pre-Clinical Products/Combination Treatment Modalities 11
Discovery Products/Combination Treatment Modalities 12
Fate Therapeutics, Inc. – Drug Profiles 13
eHSCs 13
Product Description 13
Mechanism of Action 13
R&D Progress 13
FT-101 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
FT-201 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
FT-301 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Hearing Restoration Program 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
ProHema 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
Wnt7a Activators 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
Fate Therapeutics, Inc. – Pipeline Products by Route of Administration 23
Fate Therapeutics, Inc. – Pipeline Products By Mechanism of Action 24
Fate Therapeutics, Inc. – Recent Pipeline Updates 25
Fate Therapeutics, Inc. - Dormant Projects 26
Fate Therapeutics, Inc. – Locations And Subsidiaries 27
Head Office 27
Fate Therapeutics, Inc., Recent Developments 28
Fate Therapeutics, Inc.- Press Release 28
Nov 27, 2012: Fate Therapeutics Initiates Phase II Clinical Study Of ProHema For Treatment Of Hematologic Malignancies 28
Nov 27, 2012: Protein Injection Points To Muscular Dystrophy Treatment, Scientists Discover 29
Dec 01, 2009: Fate Therapeutics’ IPSC Technology Awarded Top Industry Honors For Small Molecule And Protein Reprogramming Breakthroughs 30
Nov 16, 2009: Fate Therapeutics Closes $30 Million Series B Financing 30
Financial Deals Landscape 32
Fate Therapeutics, Inc., Deals Summary 32
Fate Therapeutics, Inc., Pharmaceuticals & Healthcare, Deal Details 33
Asset Transactions 33
Fate Therapeutics Acquires Intellectual Property Rights From The Regents Of The University Of California 33
Venture Financing 34
Fate Therapeutics Raises $9.2 Million In Venture financing 34
Fate Therapeutics Secures Venture Financing 35
Fate Therapeutics Secures $1 Million In Venture Financing 37
Fate Therapeutics Secures $30 Million In Series B Financing Round 39
Fate Therapeutics Secures $12 Million In Financing 41
Licensing Agreements 43
Fate Therapeutics Enters Into Licensing Agreement With Becton, Dickinson 43
Acquisition 45
Fate Therapeutics Acquires Verio Therapeutics 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48

List of Tables
Fate Therapeutics, Inc., Key Information 5
Fate Therapeutics, Inc., Key Facts 5
Fate Therapeutics, Inc. – Pipeline by Indication, 2012 7
Fate Therapeutics, Inc. – Pipeline by Stage of Development, 2012 8
Fate Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012 9
Fate Therapeutics, Inc. – Phase II, 2012 10
Fate Therapeutics, Inc. – Pre-Clinical, 2012 11
Fate Therapeutics, Inc. – Discovery, 2012 12
Fate Therapeutics, Inc. – Pipeline By Route of Administration, 2012 23
Fate Therapeutics, Inc. – Pipeline Products By Mechanism of Action, 2012 24
Fate Therapeutics, Inc. – Recent Pipeline Updates, 2012 25
Fate Therapeutics, Inc. - Dormant Developmental Projects,2012 26
Fate Therapeutics, Inc., Deals Summary 32
Fate Therapeutics Acquires Intellectual Property Rights From The Regents Of The University Of California 33
Fate Therapeutics Raises $9.2 Million In Venture financing 34
Fate Therapeutics Secures Venture Financing 35
Fate Therapeutics Secures $1 Million In Venture Financing 37
Fate Therapeutics Secures $30 Million In Series B Financing Round 39
Fate Therapeutics Secures $12 Million In Financing 41
Fate Therapeutics Enters Into Licensing Agreement With Becton, Dickinson 43
Fate Therapeutics Acquires Verio Therapeutics 45

List of Figures
Fate Therapeutics, Inc. – Pipeline by Indication, 2012 7
Fate Therapeutics, Inc. – Pipeline by Stage of Development, 2012 8
Fate Therapeutics, Inc. – Monotherapy Products in Pipeline, 2012 9